FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. Common Stock（FBLG）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · FBLG · 截至 2025年9月30日
股东结构概览
53
机构持有人数
▼ 6 vs Q2
$3.25M
机构持仓总市值
▼ $498,930 vs Q2
2.10M
总流通股
freeFloat 76.49%
5.35M
13F 申报持股数
▼ 619,007 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
FBLG 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 1.23M | 2.86% | 2.86% | $673.64M | Nov 7, 2025 | — held |
YORKVILLE ADVISORS GLOBAL, LP pharmaceutical preparations | 509.8K | 1.18% | 1.18% | $278.45M | Nov 18, 2025 | ▼ 334.3K |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 446.2K | 1.04% | 1.04% | $243.72M | Nov 14, 2025 | ▼ 34.4K |
BLACKROCK, INC. pharmaceutical preparations | 439.8K | 1.02% | 1.02% | $240.20M | Nov 12, 2025 | ▼ 311.1K |
LANDSCAPE CAPITAL MANAGEMENT, L.L.C. pharmaceutical preparations | 350.0K | 81.26% | 81.26% | $191.17M | Nov 13, 2025 | NEW |
GTS SECURITIES LLC pharmaceutical preparations | 308.7K | 71.66% | 71.66% | $168.53M | Nov 14, 2025 | NEW |
CASCADE FINANCIAL PARTNERS, LLC pharmaceutical preparations | 298.1K | 69.20% | 69.20% | $162.81M | Oct 21, 2025 | ▲ 7.5K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 288.9K | 67.08% | 67.08% | $157.91M | Nov 12, 2025 | — held |
CITADEL ADVISORS LLC pharmaceutical preparations | 211.1K | 49.02% | 49.02% | $115.32M | Nov 14, 2025 | ▼ 22.2K |
CERITY PARTNERS LLC pharmaceutical preparations | 125.9K | 29.23% | 29.23% | $68.78M | Oct 22, 2025 | ▼ 2.2K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
8
增持
+54.1K 股8
新建仓
首次建仓19
减持
−907.9K 股0
清仓
完全退出净股数变化（前50家）
853.8K
+54.1K / −907.9K
净新增持仓人
-3
新建 8 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
FBLG 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
4
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
O'HEERON PETE CHIEF EXECUTIVE OFFICER | May 4, 2026 | Award | 92,410 | $1.38 | $127.5K | 92.4K | Form 4 ↗ |
Khoja Hamid Chief Scientific Officer | May 4, 2026 | Award | 61,607 | $1.38 | $85.0K | 61.6K | Form 4 ↗ |
Davis Jason Chief Financial Officer | May 4, 2026 | Award | 61,607 | $1.38 | $85.0K | 61.6K | Form 4 ↗ |
GARCIA RUBEN A General Counsel | May 4, 2026 | Award | 61,607 | $1.38 | $85.0K | 61.6K | Form 4 ↗ |
Khoja Hamid Chief Scientific Officer | Mar 4, 2026 | Purchase | 30,000 | $0.38 | $11.4K | 61.3K | Form 4 ↗ |
O'HEERON PETE CHIEF EXECUTIVE OFFICER | Mar 4, 2026 | Purchase | 15,872 | $0.38 | $6.0K | 5.96M | Form 4 ↗ |
O'HEERON PETE CHIEF EXECUTIVE OFFICER | Mar 3, 2026 | Purchase | 18,200 | $0.41 | $7.4K | 5.94M | Form 4 ↗ |
O'HEERON PETE CHIEF EXECUTIVE OFFICER | Mar 2, 2026 | Purchase | 17,428 | $0.35 | $6.2K | 5.92M | Form 4 ↗ |
Davis Jason Chief Financial Officer | Mar 2, 2026 | Purchase | 70,000 | $0.41 | $29.0K | 70.0K | Form 4 ↗ |
GARCIA RUBEN A General Counsel | Feb 27, 2026 | Purchase | 40,000 | $0.33 | $13.1K | 180.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
FibroBiologics, Inc. Common Stock（FBLG）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 23.51%，散户及公众持股约占剩余的 0.00%。
FibroBiologics, Inc. Common Stock 最大机构股东为 VANGUARD GROUP INC，截至 September 30, 2025 持有约 1.23 million 股，占总流通股的 2.86%。
目前共有 53 家机构持有 FBLG 股票，合计持仓市值约 $3,254,566，数据来源为最新 SEC 13F 申报。
常见问题
FBLG ownershipFibroBiologics, Inc. Common Stock（FBLG）主要由机构投资者持有，机构持股约 100.0%。最大股东为 VANGUARD GROUP INC，持股比例 2.86%。内部人员持股约 23.51%。数据来源 SEC Form 13F，截至 September 30, 2025。